B
B. Nashan
Researcher at Hochschule Hannover
Publications - 26
Citations - 848
B. Nashan is an academic researcher from Hochschule Hannover. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 14, co-authored 26 publications receiving 837 citations.
Papers
More filters
Journal ArticleDOI
Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
TL;DR: Administration of daclizumab in addition to dual immunosuppression therapy significantly reduced biopsy-proven acute rejection after renal transplantation, improved patient survival, and did not add to the toxicity of the immunOSuppressive regimen.
Journal ArticleDOI
Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation
TL;DR: Early timing of transplantation in patients with PSC is suggested to prevent formation of biliary malignancies, and regular scoring of patients with the Mayo Model risk score should be taken into consideration at scores above 4.4.
Journal ArticleDOI
Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss.
Ohmacht C,Kliem,Burg M,B. Nashan,H. J. Schlitt,Reinhard Brunkhorst,Karl-Martin Koch,Juergen Floege +7 more
TL;DR: Recurrent IgAN is a clinically relevant problem in renal transplant patients and its importance may have been underestimated in the past due to inadequate lengths of follow-up.
Journal ArticleDOI
Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
B. Nashan,H. J. Schlitt,Reinhard Schwinzer,B Ringe,Ernst R. Kuse,G. Tusch,Kurt Wonigeit,Pichlmayr R +7 more
TL;DR: The data of the study presented suggest that therapy with an anti IL-2R moAb is at least equal to ATG application according to the incidence of acute rejections and infections.
Journal ArticleDOI
Renal transplantation for patients with autoimmune diseases : Single-center experience with 42 patients
Marion Haubitz,Volker Kliem,Karl-Martin Koch,B. Nashan,H. J. Schlitt,Pichlmayr R,Reinhard Brunkhorst +6 more
TL;DR: Renal transplantation should be offered to patients with autoimmune diseases and follow-up should include the short-term control of renal and extrarenal disease activity.